Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
December 09 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Suber Huang, MD,
MBA, FASRS, Founder and CEO of the Retina Center of Ohio, will
present safety and efficacy data from Outlook Therapeutics’ Phase 3
pivotal NORSE TWO trial evaluating ONS-5010 / LYTENAVA™
(bevacizumab-vikg), an investigational ophthalmic formulation of
bevacizumab, for use in wet AMD. The presentation will take place
virtually at the 14th Asia-Pacific Vitreo-Retina Society (APVRS)
Congress on December 10, 2021 at 11:20 – 11:30 PM ET (December 11,
2021 at 12:20 – 12:30 PM HKT).
“It is exciting to see the success of the NORSE
TWO trial,” said Dr. Huang. “The clinical results from NORSE TWO
were highly significant and move Outlook Therapeutics one step
closer towards providing patients and retina specialists with the
first on-label ophthalmic bevacizumab. If approved, ONS-5010 will
avoid the potentially serious adverse events associated with
off-label repackaged IV bevacizumab from compounding
pharmacies.”
Details for the special plenary session
presentation are as follows:
Safety and Efficacy Results of
ONS-5010 – An Ophthalmic Bevacizumab from a Phase
3 Study of Monthly Intravitreal ONS-5010 in Subjects with Wet AMD
(NORSE TWO)Presenter: Suber S. Huang, MD, MBA,
FASRSSession: Plenary Session, 0087Date and time: Friday, December
10, 2021, 11:20 – 11:30 PM ET (Saturday, December 11, 2021, 12:20 –
12:30 PM HKT)
For more information and to register for this
event, please visit APVRS 2021.
About Asia-Pacific Vitreo-Retina
Society
The Asia-Pacific Vitreo-Retina Society (APVRS)
is the premier retina subspecialty organization and one of six
subspecialty organizations and 29 member organizations that
comprise the Asia Pacific Academy of Ophthalmology. Serving a
regional population of 4.5 billion individuals, the goals of the
APVRS are to develop the vitreoretinal subspecialty in the
Asia-Pacific region, to share vitreoretinal skills and knowledge
with ophthalmologists, and to promote and disseminate knowledge of
vitreoretinal diseases, eye care and eye health issues to the
general public.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024